Quinagolide in the management of prolactinoma

Pituitary

Volumn 3, Issue 4, 2000, Pages 239-249

  Schultz, P N ^a   Ginsberg, L ^a   McCutcheon, I E ^a   Samaan, N ^a   Leavens, M ^a   Gagel, R F ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Bromocriptine; CV 205 502; Prolactinoma; Quinagolide

Indexed keywords

ANTIDEPRESSANT AGENT; BROMOCRIPTINE; PROLACTIN; QUINAGOLIDE;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DEPRESSION; DROWSINESS; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FOLLOW UP; HUMAN; HYPOPHYSIS ADENOMA; INDIGESTION; MALE; NAUSEA; PREGNANCY; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; PROLACTINOMA; SIDE EFFECT; TUMOR VOLUME; VERTIGO; VOMITING;

ADOLESCENT; ADULT; AMINOQUINOLINES; CHILD; DOPAMINE AGONISTS; FEMALE; HUMANS; MALE; MIDDLE AGED; PITUITARY NEOPLASMS; PROLACTIN; PROLACTINOMA;

EID: 0034578673     PISSN: 1386341X     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1012884214668     Document Type: Article

References (32)

1. Hyperprolactinemic anovulatory syndrome
2. Serum prolactin in patients with "functionless" chromophobe adenomas before and after therapy
3. Prolactin secreting adenomas
4. Hyperprolactinemic disorders
5. The effective, safety, and tolerability of CV 205-502 in hyperprolactinemic women: A 12 month study
6. CV 205-502, a new non-ergot dopamine agonist, reduces prolactinoma size in man
7. A double-blind study comparing a new non-ergot, long-acting dopamine agonist, CV 205-502, with bromocriptine in women with hyperprolactinemia
8. Long term treatment with CV 205-502 in patients with prolactin-secreting pituitary macroadenomas
9. Treatment of prolactin-secreting pituitary macroadenomas with the long-acting non-ergot dopamine agonist CV 205-502
10. Treatment of macroprolactinomas with a new non-ergot, long-acting dopaminergic drug, CV 205-502
11. Endocrine function, psychiatric and clinical consequences in patients with mascroprokactinomas after long-term treatment with the new non-ergot dopamine agonist CV205-502
12. Cv 205-502 treatment of macroprolactinomas
13. Effect of the new dopaminergic agonist CV 205-502 on plasma prolactin levels and tumor size in bromocriptine-resistant prolactinomas
14. CV 205-502-effectiveness, tolerability, and safety over 24-month study
15. Treatment of prolactinoma with a new dopamine agonist
16. The efficacy and tolerability of CV 205-502 (a nonergot dopaminergic drug) in macroprolactinoma patients intolerant to bromocriptine
17. Effects of the dopamine agonist CV 205-502 in human prolactinomas resistant to bromocriptine
18. Prolactinomas and resistance to dopamine agonists
19. Clinical management of prolactinomas: A ten-year experience
20. Long-term treatment of macroprolactinomas with CV 205-502
21. Long-term treatment of bromocriptine-intolerant prolactinoma patients with CV 205-502
22. CV 205-502 in the treatment of tumoral and non-tumoral hyperprolactinemic states
23. Positive response to compound CV 205-502 in hyperprolactinemic patients resistant to or intolerant of bromocriptine
24. Effects of quinagolide (CV 205-502), a selective D2-agonist, on vascular reactivity in patients with a prolactin-secreting adenoma
25. Comparison among different dopamine-agonists of new formulation in the clinical management of macroprolactinomas
26. Prolactinomas resistant to bromo criptine: Long-term efficacy of quinagolide and outcome of pregnancy
27. Prolactinomas resistant to standard dopamine agonists respond to chronic cabergoline treatment
28. Diagnosis and management of prolactinomas
29. Management of pituitary adenomas
30. Rapid regression of pituitary prolactinomas during bromocriptine treatment
31. A broad spectrum of prolactin suppression by bromocriptine in hyperprolactinemic women: A study of serum prolactin and bromocriptine levels after acute and chronic administration of bromocriptine
32. Bromocriptine as primary therapy for prolactin-secreting macroadenomas: Results of a prospective multicenter study